$LLY
Eli Lilly and Company
Pharmaceutical heavyweight known for weight-loss drugs Mounjaro and Zepbound.
LLY key facts as of November 14, 2026
- Latest AI research report
- LLY Stock: Growth, Valuation and Risks (as of November 14, 2026)
- StockAlpha report sentiment
- Neutral (as of November 14, 2026)
- Analyst consensus
- Strong Buy (6 Strong Buy, 20 Buy, 4 Hold, 1 Sell, 1 Strong Sell) (as of November 1, 2026)
- Analyst price target
- $1442.44 mean (range $940.00 to $1650.00) (as of November 17, 2026)
- Sector
- Healthcare
Analysis from Nov 14, 2026
LLY Stock: Growth, Valuation and Risks
Eli Lilly's latest reported quarter exceeded EPS estimates, and new manufacturing investment and wider access to obesity medicines support its growth story. At $1,443.50 as of Friday, November 13, the share price is close to the supplied analyst consensus mean, while a high earnings multiple and execution risks complicate the outlook.
Previous Reports
LLY FAQ
What is StockAlpha's latest view on LLY?
StockAlpha's latest AI research report on Eli Lilly and Company (LLY), "LLY Stock: Growth, Valuation and Risks", was published on November 14, 2026 and rates the overall sentiment as neutral. Eli Lilly's latest reported quarter exceeded EPS estimates, and new manufacturing investment and wider access to obesity medicines support its growth story. At $1,443.50 as of Friday, November 13, the share price is close to the supplied analyst consensus mean, while a high earnings multiple and execution risks complicate the outlook.
When was the LLY research last updated?
The most recent LLY report was published on November 14, 2026.
What do analysts expect for LLY?
As of November 1, 2026, the analyst consensus on LLY is Strong Buy (6 Strong Buy, 20 Buy, 4 Hold, 1 Sell, 1 Strong Sell). As of November 17, 2026, the analyst price target is $1442.44 mean (range $940.00 to $1650.00).
Is this LLY research investment advice?
No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.
Keep exploring
- draft Eli Lilly and into a free practice contest: How to put the stock you just researched into a contest lineup at no real-money risk
- the healthcare sector brief for context on Eli Lilly and's peers: Today's sector-level news and moves around the stock